| Crohn Disease
Avsola vs Entyvio
Side-by-side clinical, coverage, and cost comparison for crohn disease.Deep comparison between: Avsola vs Entyvio with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsEntyvio has a higher rate of injection site reactions vs Avsola based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Entyvio but not Avsola, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Avsola
Entyvio
At A Glance
IV infusion
Every 6-8 weeks
TNF-alpha inhibitor
IV infusion or SC injection
Every 2 weeks (SC) or every 8 weeks (IV)
alpha4beta7 integrin antagonist
Indications
- Crohn Disease
- Ulcerative Colitis
- Rheumatoid Arthritis
- Arthritis, Psoriatic
- Psoriasis
- Ulcerative Colitis
- Crohn Disease
Dosing
Crohn Disease, Ulcerative Colitis, Arthritis, Psoriatic, Psoriasis 5 mg/kg IV induction at weeks 0, 2, and 6, followed by 5 mg/kg every 8 weeks maintenance.
Rheumatoid Arthritis 3 mg/kg IV induction at weeks 0, 2, and 6, followed by 3 mg/kg every 8 weeks maintenance, in combination with methotrexate.
Ankylosing Spondylitis 5 mg/kg IV induction at weeks 0, 2, and 6, followed by 5 mg/kg every 6 weeks maintenance.
Ulcerative Colitis, Crohn Disease Week 0 and Week 2: 300 mg IV infusion over approximately 30 minutes; Week 6 onwards: 300 mg IV infusion every 8 weeks or 108 mg SC injection every 2 weeks; discontinue if no evidence of therapeutic benefit by Week 14.
Contraindications
- Doses >5 mg/kg in patients with moderate or severe heart failure
- Previous severe hypersensitivity reaction to infliximab products, any inactive ingredient of AVSOLA, or murine proteins
- Known serious or severe hypersensitivity reaction to vedolizumab or any excipient (e.g., dyspnea, bronchospasm, urticaria, flushing, rash, increased heart rate)
Adverse Reactions
Most common (>10%) Infections (upper respiratory, sinusitis, pharyngitis), infusion-related reactions, headache, abdominal pain
Serious Pneumonia, cellulitis, abscess, skin ulceration, sepsis, bacterial infection, lymphoma, hepatotoxicity
Postmarketing Neutropenia, agranulocytosis, interstitial lung disease, Stevens-Johnson Syndrome, toxic epidermal necrolysis, acute liver failure, anaphylactic shock, cerebrovascular accidents, myocardial ischemia
Most common (>=3%) nasopharyngitis, headache, arthralgia, nausea, pyrexia, upper respiratory tract infection, fatigue, cough, bronchitis, influenza, back pain, rash, pruritus, sinusitis, oropharyngeal pain, pain in extremities
Serious infusion-related reactions including anaphylaxis, infections (anal abscess, sepsis, tuberculosis, Listeria meningitis, giardiasis, cytomegaloviral colitis), liver injury (elevated transaminases, hepatitis), malignancies
Postmarketing anaphylaxis, acute pancreatitis, interstitial lung disease, pneumonitis
Pharmacology
TNF-alpha inhibitor; chimeric IgG1kappa monoclonal antibody that neutralizes TNFalpha by binding with high affinity to the soluble and transmembrane forms of TNFalpha, inhibiting binding of TNFalpha with its receptors.
Vedolizumab is a humanized IgG1 monoclonal antibody that specifically binds to the alpha4beta7 integrin and blocks its interaction with mucosal addressin cell adhesion molecule-1 (MAdCAM-1), inhibiting the migration of memory T-lymphocytes into inflamed gastrointestinal tissue; the mechanism is gut-selective and does not affect the alpha4beta1 or alphaEbeta7 integrins or VCAM-1 interactions.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Avsola
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (10/12) · Qty limit (0/12)
Entyvio
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (5/12) · Qty limit (9/12)
UnitedHealthcare
Avsola
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Entyvio
- Covered on 4 commercial plans
- PA (4/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Avsola
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (0/3)
Entyvio
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Avsola.
Cost estimate not availableAssistance Fund: Crohn's Disease: Waitlist
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
AvsolaView full Avsola profile
EntyvioView full Entyvio profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.